By Turna Ray
With a $200 million investment, Japanese drug developer Eisai last week launched a US-based personalized medicine subsidiary called H3 Biomedicine that will apply genetics and novel chemistry to develop tailored cancer treatments.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In Cell this week: biobank of colorectal cancer organoids, ancient wolf genome analysis, and more.
With cloud computing becoming more attractive to researchers, Nature News offers some tips on how to get going.
In a series of articles, medical journals debate the necessity of conflict-of-interest policies.
Irwin Rose, who won the 2004 Nobel Prize in Chemistry for his work on ubiquitin-mediated protein degradation, has died.